Wealthcare Advisory Partners LLC Has $2.44 Million Stake in Gilead Sciences, Inc. $GILD

Wealthcare Advisory Partners LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 20.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,347 shares of the biopharmaceutical company’s stock after selling 4,992 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Gilead Sciences were worth $2,444,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Paulson Wealth Management Inc. boosted its position in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 67 shares during the period. Essex Financial Services Inc. increased its position in Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares during the period. Davidson Trust Co. increased its position in Gilead Sciences by 4.1% during the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after acquiring an additional 74 shares during the period. Alpha Cubed Investments LLC raised its stake in Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after purchasing an additional 75 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its stake in Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after purchasing an additional 76 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead is partnering with Nucleai to deploy AI-powered tissue analytics across its global antibody-drug conjugate programs. The technology could accelerate biomarker discovery, standardize tumor-sample analysis and improve precision-oncology development, potentially strengthening Gilead’s longer-term pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Gilead exercised an option to exclusively license a preclinical bispecific program from MacroGenics, triggering a $10 million payment to its partner. The move expands Gilead’s oncology assets and signals continued investment in potential next-generation cancer treatments, although the program remains early stage. MacroGenics Announces $10 Million Milestone Following Gilead License
• Positive Sentiment: Analysts cited a consensus price target of $158.04, indicating potential upside relative to recent trading levels and continued confidence among covering analysts. Gilead Receives $158.04 Consensus Target Price
• Positive Sentiment: Gilead’s second-quarter revenue rose approximately 10% year over year to $7.8 billion and exceeded expectations. The reported loss was primarily affected by an $11.2 billion one-time acquired in-process research and development write-off, while adjusted results were better than consensus. GILD Attractive Biotech Stock With Solid Base Revenue Growth
• Neutral Sentiment: Unusually heavy call-option buying points to increased bullish trading interest, but options activity is speculative and does not by itself change Gilead’s fundamentals.
• Neutral Sentiment: Coverage of Gilead’s second-quarter earnings call may provide additional details on pipeline progress and management priorities, though no specific new financial catalyst was provided in the supplied report. Analyst Questions From Gilead’s Q2 Earnings Call
• Negative Sentiment: Erste Group Bank slightly reduced its FY2026 EPS forecast to a $0.75 loss from a $0.74 loss and trimmed its FY2027 estimate to $9.57 from $9.59. Although the changes are small, they indicate mildly softer expectations and contrast with the $0.50 consensus loss forecast for the current year.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the sale, the chief executive officer owned 592,133 shares in the company, valued at $77,160,851.23. The trade was a 2.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 82,000 shares of company stock worth $10,641,790. Insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Up 0.1%

GILD opened at $135.87 on Thursday. The company has a market cap of $168.47 billion, a P/E ratio of -50.89 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company’s 50 day moving average is $129.75 and its 200-day moving average is $136.42. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.01 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. Gilead Sciences’s dividend payout ratio is -122.85%.

Analyst Ratings Changes

GILD has been the subject of a number of recent research reports. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $133.00 to $155.00 in a report on Monday, July 6th. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, April 17th. Royal Bank Of Canada boosted their price target on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. Weiss Ratings downgraded Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Tuesday. Finally, Daiwa Securities Group lowered their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 19th. Twenty-four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.